- Home
- SPRO vs CNTY Comparison
SPRO vs CNTY Comparison
Compare SPRO & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRO | CNTY |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | 3756 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 40.8M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SPRO | CNTY |
|---|---|---|
| Price | $2.82 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 763.5K | 71.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 51.31 |
| EPS | ★ N/A | N/A |
| Revenue | $66,802,000.00 | ★ $430,529,000.00 |
| Revenue This Year | N/A | $7.17 |
| Revenue Next Year | $300.00 | $3.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | 10.82 |
| 52 Week Low | $1.80 | $1.23 |
| 52 Week High | $3.09 | $2.85 |
Technical Indicators
Market Signals| Indicator | SPRO | CNTY |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 52.52 |
| Support Level | $2.18 | $1.40 |
| Resistance Level | $2.90 | $1.47 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 49.14 | 74.80 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.